Telix ASX TLX Breaking News & Current Commentary, page-144

MNB they are tuned in to your excellent posts ... Here is your Monday reply as requested

Extract.. Headline

The new separate payment rule will apply to Illuccix® after its pass-through status expires, from July 1, 2025.

It will also apply to Telix’s pipeline of investigational diagnostic imaging agents – TLX007-CDx, a new product for PSMA imaging of prostate cancer, TLX250-CDx (Zircaix®2) for kidney cancer imaging, and TLX101-CDx (Pixclara®2) for brain cancer (glioma) imaging – if approved and reimbursed under CMS, and after pass-through expires.

Telix has continued to invest in innovation in prostate cancer imaging for the benefit of physicians and patients. Should TLX007-CDx be approved in the U.S.3, Telix will be the only company with two PSMA-PET imaging agents on the market, enabling broader patient reach, including into currently underserved populations, and with greater flexibility to offer the product most suitable for a patient based on their clinical profile, indication and eligibility for reimbursement. This may be particularly beneficial for any Medicare patients currently subject to a copayment in hospital outpatient settings.